Osvaldo Padron, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Boston Scientific at 55.9% of the total. Reporting peaked in 2024 at $6,614 and has fallen 89.4% since, to $701 in 2025.
Across 384 payments — averaging $43.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$9K
- Axonics, Inc.$3K
- Bluewind Medical$536
- AbbVie$483
- Astellas Pharma US Inc$471
- Endo Pharmaceuticals Inc.$388
- plus $2K from 31 others
Across 337 payments — averaging $3951.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Laborie Medical Technologies Corp.$305K
- AbbVie$242K
- Ferring Pharmaceuticals AS$139K
- Ferring International Pharmascience Center US$138K
- Boston Scientific$117K
- Sumitomo Pharma America, Inc.$107K
- plus $284K from 7 others
What the payments were for
- Speaking & faculty fees$5,87335%
- Travel & lodging$8455%
- Food & beverage$9,93959%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 150 | $9,363 |
| Axonics, Inc. | 66 | $3,335 |
| Bluewind Medical | 7 | $536 |
| AbbVie(2 entities) | 30 | $483 |
| Astellas Pharma US Inc | 24 | $471 |
| Endo Pharmaceuticals Inc. | 17 | $388 |
| Johnson & Johnson(2 entities) | 5 | $293 |
| Sumitomo Pharma America, Inc. | 12 | $249 |
| Pfizer | 13 | $238 |
| Bayer | 8 | $142 |
| Endo USA, Inc. | 4 | $109 |
| Amgen | 5 | $109 |
| Myovant Sciences Inc. | 6 | $106 |
| Antares Pharma, Inc. | 2 | $100 |
| Procept Biorobotics Corporation | 3 | $88 |
| Teleflex LLC | 2 | $86 |
| KARL Storz Endoscopy-america | 2 | $75 |
| Dendreon Pharmaceuticals LLC | 2 | $68 |
| Olympus America Inc. | 2 | $58 |
| Merck | 3 | $57 |
| Coloplast | 2 | $38 |
| Integra Lifesciences Corporation | 2 | $37 |
| Baxter Healthcare | 1 | $32 |
| Tolmar, Inc. | 2 | $32 |
| Immunitybio, Inc. | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Telix Pharmaceuticals | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Metuchen Pharmaceuticals | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Angiodynamics, Inc. | 1 | $18 |
| Urovant Sciences Inc | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Mckesson Medical-surgical, Inc. | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$959
- Axonics$959
- Bulkamid$670
- REVI$260
- AMS$233
- GENERAL - THERAPIES$164
- RENOVA$152
- GREENLIGHT$135
- Spectra$125
- GENERAL ERECTILE DYSFUNCTION$114
- Tremfya$108
- AMS 700$106
How this compares
$16,755 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 160 | $153,001 |
| Lupron DepotLeuprolide Acetate | 16 | $96,855 |
| OrgovyxRelugolix | 30 | $76,557 |
| PremarinEstrogens, Conjugated | 69 | $31,421 |
| GemtesaVibegron | 43 | $30,591 |
| EligardLeuprolide Acetate | 13 | $16,888 |
| FirmagonDegarelix Acetate | 12 | $7,190 |
| Testosterone | 44 | $5,481 |
| Testosterone Cypionate | 91 | $3,073 |
| Tamsulosin Hcl | 304 | $2,947 |
| Tadalafil | 27 | $2,670 |
| Solifenacin Succinate | 22 | $2,394 |
| Estradiol | 26 | $1,614 |
| Potassium Citrate ErPotassium Citrate | 26 | $1,189 |
| Methenamine Hippurate | 18 | $1,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $471 | $153,001160 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $249 | $107,14873 claims |
| AbbVieLupron Depot | $483 | $96,85516 claims |
| PfizerPremarin | $238 | $31,42169 claims |
| Ferring Pharmaceuticals Inc.Firmagon | $28 | $7,19012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.
Other urology in Tampa
- Rafael CarrionTampa$240K
- Raviender BukkapatnamTampa$115K
- Trushar PatelTampa$88K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.